OncologyOnline.net

Oncology Xagena

Xagena Mappa
Xagena Newsletter
OncologiaMedica.net
Pneumobase.it

The objective of the study was to maintain living, interactive evidence ( LIvE ) on the benefits and harms of different treatment options in adults with cancer-associated thrombosis ( CAT ). Resear ...


Two-year ( 25.4 months minimum; 32.9 months median ) follow-up results from analyses of the phase 3 CheckMate -9ER trial, have demonstrated sustained survival and response rate benefits, as well as he ...


A systematic review and meta-analysis of 36 randomized clinical trials has suggested an association between the use of ICIs administered with CT and an increased risk of infections in patients with so ...


A systematic review and meta-analysis of 36 randomized clinical trials has suggested an association between the use of immune checkpoint inhibitors ( ICIs ) administered with chemotherapy and an incre ...


In CheckMate 577, Nivolumab ( Opdivo ) has demonstrated a significant and clinically meaningful improvement in disease-free survival ( DFS; primary endpoint ) versus placebo and was well tolerated in ...


New data from the phase 1/2 trial of Mobocertinib orally administered in previously treated patients with epidermal growth factor receptor ( EGFR ) exon20 insertion+ metastatic non-small cell lung can ...


Results from the phase 2 cohort of the CodeBreaK 100 clinical study evaluating investigational Sotorasib ( AMG 510 ) in 126 patients with KRAS G12C-mutated advanced non-small cell lung cancer ( NSCLC ...


New data from the phase 1 CHRYSALIS study, which has evaluated Amivantamab in patients with metastatic or unresectable non-small cell lung cancer ( NSCLC ) and epidermal growth factor receptor ( EGFR ...


Updated data from GARNET cohort F evaluating Dostarlimab in mismatch repair-deficient ( dMMR ) non-endometrial advanced solid cancers were presented at the 2021 American Society of Clinical Oncology ...


Patients with autoimmune disease and lung cancer pose a multidisciplinary treatment challenge, particularly with the advent of immunotherapy. However, the association between autoimmune disease and ...


NICOLAS is the first completed single-arm phase II trial in stage III non-small-cell lung cancer ( NSCLC ) examining hierarchically first the safety and then the efficacy of adding Nivolumab ( Opdivo ...


Consolidation Durvalumab after chemoradiation ( CRT ) is the current standard of care for locally advanced non-small-cell lung cancer ( NSCLC ). Researchers have hypothesized that adding immunothe ...


Non-small-cell lung cancer ( NSCLC ) is terminal in most patients with locally advanced stage disease. Researchers have assessed the antitumour activity and safety of neoadjuvant chemoimmunotherapy ...


Sintilimab ( Tyvyt ), an anti–programmed death 1 antibody, plus Pemetrexed and Platinum had revealed promising efficacy for nonsquamous non-small-cell lung cancer ( NSCLC ) in a phase 1b study. Re ...


Researchers have retrospectively examined progression-free survival ( PFS ) and response by ALK fluorescence in-situ hybridization ( FISH ) status in patients with advanced ALK immunohistochemistry ( ...